QuickStrip
Share
QuickStripTM is an oral thin dissolvable strip that can deliver the active ingredient precisely and
04/13/2026
Rapid Dose Therapeutics is advancing the next phase of its Burlington facility expansion targeting global medical markets to strengthen pharmaceutical manufacturing capability, support future regulatory pathways, and expand the long-term strategic value of its QuickStrip™ platform.
This is more than a facility upgrade. It is a disciplined investment in infrastructure designed to support scale, flexibility, and future participation in regulated global medical markets.
Why this matters:
• Global prescription drug sales are forecast to reach approximately US$1.7 trillion by 2030.
• The global medical cannabis market is projected to reach approximately US$65.9 billion by 2030.
• As demand grows for compliant, non-combustible, patient-friendly delivery formats, manufacturing readiness becomes a strategic advantage.
https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-advances-pharmaceutical-manufacturing-expansion-with-burlington-facility-upgrades-targeting-global-medical-markets/
Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets - Rapid Dose Therapeutics BURLINGTON, ON — April 13, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at i...
In June, QuickStrip™ by Rapid Dose Therapeutics was featured in RecoverCann’s WGY6 campaign for Men’s Mental Health and PTSD Awareness Month—spotlighting wellness-oriented innovations
This visibility aligns with a major research milestone: QuickStrip™ is currently being studied in an NFL-funded clinical trial, led by researchers at the University of Regina and the University of Saskatchewan. The study is evaluating the pharmacokinetics of CBD when delivered through RDT’s QuickStrip™ compared to traditional oral formats. The strips are rectangular oral thin films infused with cannabis extract, which, when placed under the tongue, dissolve and release the cannabis extract into the mucus membranes of the mouth.
CEO.CA has issued a press release as part of its latest Inside the Boardroom series, featuring Rapid Dose Therapeutics.
You can read the full press release here:
https://lnkd.in/eh3t-HvG
05/27/2025
Patented Innovation in Ni****ne Delivery
Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Ni****ne Delivery Technology.
These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use.
https://rapid-dose.com/rapid-dose-therapeutics-and-aavishkar-oral-strips-file-two-key-patents-for-innovative-ni****ne-delivery-technology/
****neInnovation $DOSE
Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Ni****ne Delivery Technology - Rapid Dose Therapeutics BURLINGTON, ON – May 26, 2025 – Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian life sciences company specializing in innovative drug delivery solutions through its QuickStrip™ platform, today announced the filing of two critical patent applications in pa...
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
1121 Walker's Line, Unit 3A
Burlington, ON
L7N2G4
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |
